Avulux Won a De Novo and Created the Category Its Competitors Will File Into
- The FDA granted Avulux De Novo marketing authorisation on 24 August 2026, establishing a new recognised classification of precision optical filter. The lens blocks light at 480 nm and 590 nm while passing the rest of the visible spectrum, indicated to decrease the impact of light sensitivity in patients diagnosed with episodic migraine aged 12 and older.
- It is authorised for over-the-counter use and available without a prescription through eye care providers, optical practices and authorised partners. It is worn like ordinary eyeglasses, with or without a vision prescription, and should not alter usual care including medication.
- Avulux enters authorisation with a commercial base already built: more than 50,000 wearers and over 1,400 eye care providers across the US and Canada. Migraine affects more than 45 million people in the US, as many as 90% of whom experience light sensitivity, with up to 60% of attacks triggered by light or glare.
- The company cites randomised controlled trials and real-world experience. The two studies referenced are a randomised double-blind trial published in the Journal of Clinical Neuroscience in 2023, whose first author is Avulux’s chief executive, and a 2025 conference abstract measuring photosensitivity discomfort thresholds in healthy volunteers.
CI read
De Novo authorisation is being read as a moat. It is closer to the opposite. The pathway exists to create a classification where none existed, and a classification is precisely what every later entrant gets to file against.
- Going first through a De Novo builds the road behind you. Avulux owns the first and only claim today and has also created the regulatory category, so rivals file 510(k) submissions against it rather than repeating the De Novo. Price the exclusivity window, not the authorisation itself.
- Over-the-counter status means the authorisation legitimises rather than gates. No prescription is required and distribution is unchanged. What Avulux gains is a recognised category optometrists can dispense against and a name patients can request, layered onto 50,000 existing wearers and 1,400 providers.
- The cited evidence is thinner than the announcement implies. Of two references, one is a 2023 randomised trial first-authored by the company’s chief executive, and the other is a conference abstract in healthy volunteers rather than migraine patients. Ask for the full De Novo decision summary before treating this as settled.